WEDNESDAY, SEPTEMBER 28, 2016

Visterra medication proves effective against influenza strains

Visterra medication proves effective against influenza strains. | Courtesy of biology.usf.edu

Visterra Inc., a clinical-stage biotechnology company, recently published data that shows the effectiveness of its VIS410 in protecting people from both seasonal and potentially pandemic influenza strains.

Visterra uses its own proprietary technology platform to identify unique disease targets. It also uses the platform to create innovative therapeutics for infectious diseases.

The publication is the result of Visterra’s preclinical results of its novel monoclonal antibody, VIS410. The treatment was designed against seasonal as well as pandemic influenza.

“Emerging strains of influenza represent a significant public health threat, including the recently-emerged H7N9 strains, which cause pneumonia with acute respiratory distress syndrome and has a high mortality rate,” Zach Shriver, Ph.D., vice president of research at Visterra, said. “With the potential to address this important unmet medical need, we are very encouraged by these new data further demonstrating the effectiveness of VIS410, including a significant survival benefit, in an H7N9 animal model. Visterra’s novel monoclonal antibody, VIS410, targets a unique, conserved epitope on influenza A, and we are developing it as a single administration for the treatment of seasonal and pandemic influenza. We recently initiated a placebo-controlled Phase 2 challenge trial of VIS410 in healthy subjects administered an influenza virus in advance of receiving either VIS410 or placebo. We anticipate data from this trial will be available later this year.”

Further details are available in the Proceedings of the National Academy of Sciences journal.

Organizations in this story

Visterra Inc One Kendall Square, Cambridge, MA 02139, United States Cambridge, MA 02139

Get notified the next time we write about Visterra Inc!